Tracking the Pivotal Point of Edwards Lifesciences: Heart Specialist Surprises With Strong Quarter!
Reading Time: 1 minute
Edwards Lifesciences is a medical technology company specializing in heart valves, bypass cannulas, and monitoring solutions. On July 24, impressive figures for Q2 were presented, significantly exceeding analyst expectations. Revenue increased by 11.6% to $1.53 billion, surpassing the consensus estimate of $1.49 billion. Adjusted EPS also exceeded expectations at 69 cents, compared to the anticipated 62 cents. Due to this strong performance, management raised its revenue forecast for the full year to $5.90-6.10 billion. The optimistic outlook...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
